| Abbreviation | Full term |
| ADC | Antibody–drug conjugate |
| ADCC | Antibody-dependent cellular cytotoxicity |
| ADCP | Antibody-dependent cellular phagocytosis |
| AFP | Alpha-fetoprotein |
| APC | Antigen-presenting cell |
| BRAF | B-Raf proto-oncogene |
| BRCA | Breast cancer susceptibility gene |
| BTC | Biliary tract cancer |
| CAR-T | Chimeric antigen receptor T cell |
| CCA | Cholangiocarcinoma |
| CDC | Complement-dependent cytotoxicity |
| CD | Cluster of differentiation |
| CLDN18.2 | Claudin 18.2 |
| CPS | Combined positive score |
| CRC | Colorectal cancer |
| CTLA-4 | Cytotoxic T-lymphocyte-associated protein 4 |
| dMMR | Deficient mismatch repair |
| EGFR | Epidermal growth factor receptor |
| EMA | European Medicines Agency |
| ERBB2 | Erb-b2 receptor tyrosine kinase 2 |
| ESCC | Esophageal squamous cell carcinoma |
| ESMO | European Society for Medical Oncology |
| FDA | United States Food and Drug Administration |
| FGF | Fibroblast growth factor |
| FGFR2 | Fibroblast growth factor receptor 2 |
| FGFR2b | Fibroblast growth factor receptor 2b |
| FISH | Fluorescence in situ hybridization |
| GC | Gastric cancer |
| GEJ | Gastroesophageal junction |
| GI | Gastrointestinal |
| GIST | Gastrointestinal stromal tumor |
| GPC3 | Glypican-3 |
| HCC | Hepatocellular carcinoma |
| HER2 | Human epidermal growth factor receptor 2 |
| HPV | Human papillomavirus |
| IDH1 | Isocitrate dehydrogenase 1 |
| IDH2 | Isocitrate dehydrogenase 2 |
| IHC | Immunohistochemistry |
| ISH | In situ hybridization |
| KIT | KIT proto-oncogene receptor tyrosine kinase |
| mAb | Monoclonal antibody |
| MMR | Mismatch repair |
| MSI | Microsatellite instability |
| MSI-H | Microsatellite instability-high |
| MSS | Microsatellite stable |
| NGS | Next-generation sequencing |
| NK | Natural killer |
| NTRK | Neurotrophic tyrosine receptor kinase |
| PALB2 | Partner and localizer of BRCA2 |
| PD-1 | Programmed cell death protein 1 |
| PD-L1 | Programmed death-ligand 1 |
| PDGFRA | Platelet-derived growth factor receptor alpha |
| PlGF | Placental growth factor |
| PRRT | Peptide receptor radionuclide therapy |
| RAS | Rat sarcoma viral oncogene homolog |
| SSTR | Somatostatin receptor |
| T-DXd | Trastuzumab deruxtecan |
| TKI | Tyrosine kinase inhibitor |
| TLA | Three-letter acronym |
| TRK | Tropomyosin receptor kinase |
| VEGF | Vascular endothelial growth factor |
| VEGFR | Vascular endothelial growth factor receptor |
| WT | Wild-type |